Search Resources (English): Women and Health Protection (WHP)

Results 51 - 60 of 63

Results

Evidence for Caution: Women and Statin Use  
http://www.whp-apsf.ca/pdf/statinsEvidenceCaution.pdf

Discusses a class of cholesterol-lowering drugs called statins and the risks to women.

 (See Details)
Published: June 2007
Pregnancy and mental health: a review of popular pregnancy information sources   
http://www.whp-apsf.ca/pdf/Pregnancy%20%20Mental%20Health.pdf

Examines the information available to the Canadian public through popular pregnancy information sources to assess gaps in information available and determine the extent, if any, of the difference between public information and medical literature on this topic.

 (See Details)
Published: March 2009
Reflections on Depo Provera: Contributions to Improving Drug Regulation in Canada  
http://www.whp-apsf.ca/pdf/reflectionsOnDepoProvera.pdf

Examines the ongoing story of Depo Provera, including: its regulatory history; how it has been and continues to be used, and; what is known about its safety profile.

 (See Details)
Published: October 2007
Drugs, devices and women's health: advocating for protection   
http://www.acewh.dal.ca/pdf/Looking%20Back%20presentations/Rochon%20Ford%20-%20Drugs,%20Devices%20and%20Women%27s%20Health.pdf

Powerpoint presentation on some of the work of Women and Health Protection, including research into the effects of Direct-to-Consumer Advertising (DTCA) of prescrption drugs, the CanWest Charter Challenge, a public forum on silicone gel breast implants, and women and statins.

 (See Details)
Published: March 2009
Evidence for caution: What women need to know about statins  
http://www.whp-apsf.ca/pdf/Evidence%20for%20Caution%20-%20Facts%20to%20Act%20On.pdf

Based on Evidence for Caution:  Women and Statin Use (2007) by Harriet Rosenberg and Danielle Allard.

 (See Details)
Published: 2009
Ten good reasons to be concerned about the human papillomavirus (HPV) vaccination campaign  
http://www.whp-apsf.ca/pdf/Ten%20Good%20Reasons%20.pdf

Outlines the main concerns that the Fédération du Québec pour le planning des naissances (FQPN), along with many women’s, teachers’, nurses’ and youth organizations, have about the vaccination program that was introduced in Quebec against the human papillomavirus (HPV) in hopes of reducing rates of cervical cancer.

Translated and adapted by Women and Health Protection and the Canadian Women’s Health Network.

 (See Details)
Published: October 2008
The HPV Vaccine: Information for Parents (and others considering it)  
http://www.whp-apsf.ca/pdf/HPV%20Vaccination%20-%20Information%20for%20Parents%20and%20Others.pdf

Plain language guide explaining the HPV Vaccine

 (See Details)
Published: January 2009
Breast implants public forum: concerns about Health Canada's process  
http://www.whp-apsf.ca/en/documents/concerns.html

Ann Rochon Ford, coordinator of Women and Health Protection composed a letter of concerns around the process of Health Canada's regulation hearings for breast implant use in Canada.  The link includes the reply from Health Canada and further concerns raised by Rochon Ford.

 (See Details)
Published: 2005
Complaint letter to Minister Tony Clement regarding DTCA of celebrex  
http://www.whp-apsf.ca/en/documents/celebrex_letter.html

This letter raises concerns about the risks to public health of an advertisement for a prescription drug, Celebrex (celecoxib), that aired on Canadian television. The letter asks Minister Tony Clement to take immediate regulatory action to stop this advertising campaign and to impose sanctions on the sponsor, Pfizer, to prevent future violations.

 (See Details)
Published: March 14, 2006
Complaint letter to Health Canada: Pfizer "toe-tag" ad  
http://www.whp-apsf.ca/en/documents/pfizerCampaign.html

This letter to Health Canada argues that the pharmaceutical manufacturer, Pfizer, has been running television ads with misleading information on cardiovascular risks and using Canadian's fear of death from heart disease in order to promote sales of its product.  It urges Health Canada to take regulatory action on this campaign.

 (See Details)
Published: January 2004